This is Why Wall Street Firms are Bullish on Boston Scientific Corporation (BSX)

Core Insights - Boston Scientific Corporation (NYSE:BSX) is positioned as a strong investment opportunity for 2026, highlighted by its acquisition of Valencia Technologies, which enhances its urology and pelvic health portfolio with the FDA-approved eCoin System for urge urinary incontinence [1] - The company has received positive endorsements from major financial institutions, including JPMorgan and UBS, indicating strong market positioning and growth potential in the medical device sector [2][4] Group 1: Acquisition and Product Development - Boston Scientific has agreed to acquire Valencia Technologies, which produces the eCoin System that utilizes tibial nerve stimulation, showing a 68% response rate in clinical trials [1] - The acquisition is expected to close in the first half of 2026 and will have minimal impact on adjusted earnings [1] Group 2: Market Position and Financial Performance - Boston Scientific is recognized as a leader in minimally invasive medical technologies, supported by its cardiovascular, rhythm management, and endoscopy product lines, which contributed to third-quarter revenue exceeding analyst expectations [3] - UBS has set a price target of $140 for the stock, citing a favorable risk-reward profile due to high-growth business segments [4] Group 3: Future Growth Projections - UBS anticipates that Boston Scientific will guide 2026 sales growth above its long-range plan of 10% to 12%, primarily driven by strong momentum in the WATCHMAN business [5] - The Electrophysiology (EP) division, which currently accounts for 17% of sales, is expected to grow to 20-25% as reiterated by CEO Mike Mahoney [4]